As you may be aware, the past 10 years have provided much insight into what has come to be called... "The Oral / Systemic Connection". There does appear to be a link to chronic inflammatory periodontal infections and systemic diseases. At Synergy Dental Group, we customize your dental care with specific Oral DNA Saliva Genetic Testing. Please visit Oral DNA LabTests to view how we use these to help personalize your care.These new, quick and non-invasive tests deliver information that will enable your dental professional to better determine the appropriate treatment plan tailored to your specific needs.

OralDNA™ Labs develop clinically useful diagnostic tests based on DNA-PCR technology for use by dental professionals. Our goal is to drive early detection and more predictable treatment outcomes in the clinical setting.


This test indentifies and measures certain bacteria in your mouth that cause gingivitis (early stage gum disease) and periodontal disease (mature gum disease).The MyPerioPath® salivary diagnostic test identifies the type and concentration of specific perio-pathogenic bacteria that are known to cause periodontal disease. MyPerioPath® helps support the clinician with better risk assessment and personalized treatment options for more predictable outcomes.


This test determines if you are more likely to develop more serious gum tissue infections, such as inflammatory periodontal disease.

OraRisk® HPV:

This test determines if you are at increased risk for HPV-related oral and throat cancers.

OraRisk® HPV Testing From OralDNA Labs

Human papillomavirus (HPV) is one of the most common virus groups in the world. According to the Centers for Disease Control, at least 20 million people in the United States are infected with HPV and there are approximately 6 million new cases each year.

Oral HPV is a manifestation of the HPV virus in the mouth and is primarily found in the oropharyngeal complex. Specific types of oral HPV are now considered to be separate and serious risk factor for developing oral cancers. Early detection and identification of the presence or absence of oral HPV is important, as early oral HPV infections do not typically cause any clinical signs or symptoms.

The OraRisk® HPV test is a non-invasive, easy-to-use screening tool to identify the type(s) of oral HPV, a mucosal viral infection that could potentially lead to oral cancer. OraRisk® HPV enables the clinician to establish increased risk for oral cancer and determine appropriate referral and monitoring conditions.

Celsus One™ salivary DNA tests to evaluate gene markers related to inflammatory response. Tests 8 genetic markers.

OraRisk® HSV Type 1 and HSV Type 2 Testing from OralDNA Labs

OraRisk® HSV test is an accurate, sensitive and easy way to diagnose herpes simplex virus outbreaks involving the oropharynx. HSV infections are very common, yet can often be mistaken for other causes of oral vesicles, ulcers and other forms of painful oral and pharyngeal lesions. This test, offered as a simple oral rinse or a site-directed swab, helps make the correct diagnosis.

OraRisk HSV features:

  1. Clearly identifies HSV 1 or HSV 2
  2. Detects "shed virus" specific to active infections or outbreaks
  3. Oral rinse makes it easy to find infections located in remote areas
  4. Treatment recommendations are provided

Which patients should be tested?

  1. Signs or symptoms of pain in oropharyngeal mucosa
  2. History of trauma, stress or food sensitivity, with a complaint of pain or a vesicular or ulcerative lesion
  3. An immunocompromised patient with recurrent oral lesions or other systemic disease such as cancer
  4. Concern of sexually transmitted disease

OraRisk® Candida Testing From OralDNA Labs

OraRisk® Candida is the second in a series of unique tests for infections common in the oral cavity and pharynx. OraRisk® Candida identifies all common species of the yeast, Candida; which is known to cause oral thrush in patients with a normal or compromised immune system.

Candida species identification is key to treatment choice since some types of Candida are resistant to standard antifungal treatments. Additionally, our interpretative report guides the clinician with treatment recommendations.

*OraRisk® Candida is not currently available in the State of New York.

Which patients should be tested?

  1. Patients with oral infections with typical signs or symptoms
  2. Patients with recurrent oral yeast infections
  3. Patients with non-healing oral ulcers
  4. Immunocompromised patients with a wide range of signs or symptoms suggesting oral infection.

Visit the Oral DNA Website to learn more about these lab tests.

Synergy Dental Group

Accessibility Menu